Fate Therapeutics Inc (FATE)

[jondoeuk]

TAMs alter NK cell phenotype and function in part through secretion of TGF-B. The company had created a novel synthetic TGF-B receptor, which enhanced the antitumour activity of iNKs. Also, had two ''clean'' CARs, one targeting MICA/B, and even high doses of NKs don't result in the same kinds of toxicities that T-cells would.

A platform with tremendous potential and management ran it into the ground!